AU2022370513B2 - Compositions comprising ciprofloxacin and celecoxib - Google Patents

Compositions comprising ciprofloxacin and celecoxib

Info

Publication number
AU2022370513B2
AU2022370513B2 AU2022370513A AU2022370513A AU2022370513B2 AU 2022370513 B2 AU2022370513 B2 AU 2022370513B2 AU 2022370513 A AU2022370513 A AU 2022370513A AU 2022370513 A AU2022370513 A AU 2022370513A AU 2022370513 B2 AU2022370513 B2 AU 2022370513B2
Authority
AU
Australia
Prior art keywords
ciprofloxacin
celecoxib
tablet
hours
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022370513A
Other languages
English (en)
Other versions
AU2022370513A1 (en
Inventor
Alon BEN NOON
Sharon COHEN VERED
Jeffrey Sterling
Oron Yacoby-Zeevi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurosense Therapeutics Ltd
Original Assignee
Neurosense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosense Therapeutics Ltd filed Critical Neurosense Therapeutics Ltd
Publication of AU2022370513A1 publication Critical patent/AU2022370513A1/en
Application granted granted Critical
Publication of AU2022370513B2 publication Critical patent/AU2022370513B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022370513A 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib Active AU2022370513B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257130P 2021-10-19 2021-10-19
US63/257,130 2021-10-19
PCT/IL2022/051096 WO2023067592A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Publications (2)

Publication Number Publication Date
AU2022370513A1 AU2022370513A1 (en) 2024-05-16
AU2022370513B2 true AU2022370513B2 (en) 2025-09-25

Family

ID=85982158

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022370513A Active AU2022370513B2 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Country Status (9)

Country Link
US (1) US12097185B2 (enExample)
EP (1) EP4419099A4 (enExample)
JP (1) JP7857044B2 (enExample)
KR (1) KR20240090519A (enExample)
CN (1) CN118369097A (enExample)
AU (1) AU2022370513B2 (enExample)
CA (1) CA3235348A1 (enExample)
IL (1) IL312274A (enExample)
WO (1) WO2023067592A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980780B2 (en) * 2017-06-20 2021-04-20 Neurosense Therapeutics Ltd. Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP3641820B1 (en) * 2017-06-20 2022-12-28 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980780B2 (en) * 2017-06-20 2021-04-20 Neurosense Therapeutics Ltd. Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAERUNISAA, A.Y. et al., 'Release Adjustment of Two Drugs with Different Solubility Combined in a Matrix Tablet', AAPS PharmSciTech. 2019, Vol. 20, No. 142, pp. 1-8 *
CHEMPOINT, 'Methocel® K100LV' [retrieved from the internet 05/02/2025] URL: https://www.chempoint.com/en-emea/products/iff/methocel-water-soluble-cellulose-ethers/methocel-water-soluble-cellulose-ethers/methocel-k100lv Published 01/11/2020 *
TIWARI S. B. et al., 'Extended-Release Oral Drug Delivery Technologies: Monolithic Matrix Systems', In: Jain, K.K. (eds) Drug Delivery Systems. Methods in Molecular Biology. 2008, Vol. 437, p. 217-243. Humana Press *

Also Published As

Publication number Publication date
US20230120880A1 (en) 2023-04-20
EP4419099A1 (en) 2024-08-28
US12097185B2 (en) 2024-09-24
IL312274A (en) 2024-06-01
CA3235348A1 (en) 2023-04-27
AU2022370513A1 (en) 2024-05-16
CN118369097A (zh) 2024-07-19
EP4419099A4 (en) 2025-09-24
KR20240090519A (ko) 2024-06-21
JP2024539116A (ja) 2024-10-28
JP7857044B2 (ja) 2026-05-12
WO2023067592A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US12357627B2 (en) Pharmaceutical compositions of cabozantinib
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US20020182256A1 (en) Novel oral dosage form for carvedilol
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
HUT75164A (en) Opioid formulations having extended controlled release
CZ20024216A3 (cs) Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
US20130344148A1 (en) Oral Composition
WO2005027876A1 (en) Pharmaceutical compositions of benzimidazole and processes for their preparation
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
AU1456999A (en) Novel oral dosage form for carvedilol
SK286865B6 (sk) Multičasticový farmaceutický prostriedok s riadeným uvoľňovaním selektívneho inhibítora spätného príjmu serotonínu a jeho použitie
CA3163555A1 (en) Methotrexate dosage form
US12097185B2 (en) Compositions comprising ciprofloxacin and celecoxib
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
WO2023089553A1 (en) Controlled release formulations of flavoxate and process for preparation thereof
BR112024007727B1 (pt) Composições que compreendem ciprofloxacina e celecoxibe
HK40113418A (zh) 包含环丙沙星和塞来昔布的组合物
WO2026064388A1 (en) Fixed dose combination of flavoxate and alpha-blockers, and formulations and manufacturing processes thereof
US20060257483A1 (en) Controlled release bupropion dosage forms
WO2026018274A1 (en) Triple layer tablet formulation of telmisartan
WO2013111147A1 (en) Extended release compositions of nevirapine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)